Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 1/20 | 0.61 |
| ▸ | CTSG | P08311 | 1/20 | 0.61 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.61 |
| ▸ | CMA1 | P23946 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | ESRRG | P62508 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5707056 | 0.92 | PRSS1 (0.56) | PRSS1CTSGCTRB1CMA1GAA | |
| SCHEMBL3068094 | 0.89 | MAPK14 (0.52) | PRSS1CTSGCTRB1CMA1GAA | |
| SCHEMBL25752880 | 0.83 | PRSS1 (0.67) | PRSS1CTSGCTRB1CMA1GAA | |
| SCHEMBL3112777 | 0.83 | CYP2C19 (0.47) | — | |
| SCHEMBL10224288 | 0.83 | PRSS1 (0.67) | PRSS1CTSGCTRB1CMA1GAA | |
| SCHEMBL29182131 | 0.83 | PRSS1 (0.62) | PRSS1CTSGCTRB1CMA1GAA | |
| SCHEMBL21590340 | 0.81 | PRSS1 (0.65) | PRSS1CTSGCTRB1CMA1GAA | |
| SCHEMBL17833433 | 0.81 | GAA (0.59) | PRSS1CTSGCTRB1CMA1GAA | |
| SCHEMBL8499984 | 0.81 | ACACB (0.51) | — | |
| SCHEMBL7676183 | 0.80 | PRSS1 (0.63) | PRSS1CTSGCTRB1CMA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367700-B2 | Substituted 4-(1.2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators | GRUENENTHAL GMBH (DE) | 2013-02-05 | — | — | US | disclosed |
| EP-2358681-A1 | SUBSTITUTED 4-(1,2,3,4-TETRAHYDROISOCHINOLIN-2-YL)-4-OXO-BUTYRIC ACID AMIDE AS KCNQ2/2 MODULATORS | Grünenthal GmbH (DE) | 2011-08-24 | — | — | EP | disclosed |
| WO-2010075973-A1 | SUBSTITUTED 4-(1,2,3,4-TETRAHYDROISOCHINOLIN-2-YL)-4-OXO-BUTYRIC ACID AMIDE AS KCNQ2/2 MODULATORS | Grünenthal GmbH (DE) | 2010-07-08 | — | — | WO | disclosed |
| US-20100152234-A1 | Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators | GRUNENTHAL GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
| EP-1440052-B1 | BENZAMIDE DERIVATIVES AS ANTAGONISTS OF OREXIN RECEPTORS | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1577291-A1 | Phenylethanolamine derivatives as beta-2 agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152234-A1 | Substituted 4-(1,2,3,4-tetrahydroisoquinolin-2-yl)-4-oxobutyric acid amide as KCNQ2/3 modulators | KCNAB1, KCNQ2, KCNQ1 | PRSS1 4687/4885CTSG 4753/4885CTRB1 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.